方盛制药: 方盛制药第六届董事会独立董事专门会议2025年第二次临时会议决议

Core Points - The company held the second temporary meeting of the sixth board of independent directors on May 29, 2025, via remote voting, which was legally valid and complied with relevant regulations [2][3] - The meeting approved a proposal for capital increase and related transactions for its subsidiary, GuangDong Fangsheng R&D Pharmaceutical Co., Ltd. (Fangsheng R&D), aimed at enhancing its funding for drug research and development projects [2][3] - The capital increase is expected to improve the sustainability of R&D investments and mitigate the company's risks associated with new product development, ensuring no harm to minority shareholders [2][3] Summary by Sections - Meeting Details - The meeting was convened by independent director Yuan Xiong and attended by all three independent directors, confirming the quorum [2] - The proposal was submitted for review at the fourth temporary meeting of the sixth board [3] - Proposal Approval - The proposal received unanimous support with 3 votes in favor, 0 against, and 0 abstentions [3] - Independent directors involved in the voting were Gao Xueming, Du Shouying, and Yuan Xiong [3]